Variety of suitable individuals: CDEC talked about the uncertainty in the amount of people with reasonably extreme to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some individuals who're categorised as having mild or average disease might have a extreme bleeding https://hemgenix72604.blogs-service.com/66692520/detailed-notes-on-hemgenix